Galosi Andrea Benedetto, Papaveri Alessio, Castellani Daniele, Agostini Edoardo, Burattini Luciano, Dell'Atti Lucio
Department of Specialist Clinical Science and Odontostomatology, Urology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.
Department of Molecular and Clinical Science, Medical Oncology Division, Università Politecnica delle Marche, Via conca 71, 60126, Ancona, Italy.
Urol Case Rep. 2021 Mar 25;37:101660. doi: 10.1016/j.eucr.2021.101660. eCollection 2021 Jul.
Up to 19% of patients with renal cell carcinoma present with a venous thrombus at diagnosis and 1% have a thrombus extending above the diaphragm. The higher the thrombus level, the more challenging the surgery. Cavoatrial tumor thrombus usually requires circulatory arrest and sometimes cardiopulmonary by-pass. We present a case of non-metastatic renal cell carcinoma with a cavoatrial tumor thrombus in a patient who was unfit for cardiac surgery. Eight months of targeted molecular therapy downsized the tumor thrombus to inferior vena cava and allowed us to perform a radical nephrectomy with minimal cavothomy for thrombus resection.
高达19%的肾细胞癌患者在诊断时伴有静脉血栓,1%的患者血栓延伸至膈肌上方。血栓水平越高,手术难度越大。腔房肿瘤血栓通常需要循环阻断,有时还需要体外循环。我们报告一例非转移性肾细胞癌合并腔房肿瘤血栓的病例,该患者不适合心脏手术。八个月的靶向分子治疗使肿瘤血栓缩小至下腔静脉,使我们能够进行根治性肾切除术,并通过最小限度的腔静脉切开术切除血栓。